Form 4: Krystal Biotech CEO and Spouse Execute Stock Sales Under 10b5-1 Plans

Krystal Biotech's CEO, Krish S. Krishnan, and his spouse, Suma M. Krishnan, sold shares of the company's common stock on December 13, 2024, under pre-arranged 10b5-1 trading plans.

Summary

• Krish S. Krishnan, the President and CEO of Krystal Biotech, and his spouse, Suma M. Krishnan, executed sales of Krystal Biotech common stock on December 13, 2024.
• These sales were conducted under pre-established Rule 10b5-1 trading plans adopted on June 13, 2024.
• The trading plans started on September 12, 2024, and are set to terminate on September 13, 2025.
• Both plans contemplate quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
• Krishnan sold a total of 24,699 shares directly at prices ranging from $163.069 to $171.6288.
• Suma M. Krishnan sold a total of 24,390 shares at prices ranging from $163.0435 to $171.6245.
• The sales were executed in multiple trades, with the reported prices reflecting weighted average sale prices.
• Krishnan also indirectly owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 5

Explanation: The document reports routine stock sales under a pre-arranged plan, which is neither positive nor negative. It's a neutral event from an investment perspective.

Risks

• The sales by the CEO and his spouse, while under a pre-arranged plan, could be perceived negatively by some investors.
• The market may react to the sales, potentially impacting the stock price.

Future Outlook

The Rule 10b5-1 trading plans will continue until September 13, 2025, with quarterly sales of 25,000 shares each, subject to a limit price of $150.00 per share.

Industry Context

The use of 10b5-1 trading plans is a common practice for corporate insiders to sell shares while avoiding accusations of insider trading. This filing is a routine disclosure of such transactions.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard practice among publicly traded companies, including biotech firms like Krystal Biotech.
• Many executives at comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize 10b5-1 plans for stock sales.
• The reported sales are within the typical range of insider transactions for companies of Krystal Biotech's size and stage.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, although they are part of a pre-planned strategy.
• The sales do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Krystal Biotech, KRYS, insider trading, stock sales, Rule 10b5-1, Krishnan, Suma Krishnan, executive stock sales